On November 5, Viking Therapeutics fell 8.1% in Regular Trading to $25.695/share, with turnover of $29.7442 million.
The clearest recent catalyst in public information is continued digestion of the company’s late-October quarterly report. Viking Therapeutics reported third-quarter EPS of $1.55 loss, wider than consensus expectations for a $1.06 to $1.07 loss, even though the company also highlighted positive obesity-study data and a cash balance of about $960 million.
That makes the move primarily earnings-driven: the reported loss came in worse than expected, and recent market coverage linked share-price weakness to investors focusing on that earnings miss rather than pipeline progress. Earlier supportive items, including Phase 3 advancement for oral VK2735 and a Buy initiation with a $94 price target, provide background but do not appear to be the most immediate driver of this session’s decline.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments